Impact of FTO Gene Variation on Body Composition, Lipid Profile, Insulin Resistance, Advanced Glycation End-Products and Ghrelin Levels in Response to Hypocaloric, Protein Rich-Diet
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Dr Bibi Hajira, PhD
- Phone Number: 03015287833
- Email: ghanihajira@gmail.com
Study Contact Backup
- Name: Dr Muhammad Omar Malik, PhD
- Phone Number: 03335196243
- Email: omarmalik786@gmail.com
Study Locations
-
-
KPK
-
Peshawar, KPK, Pakistan, 25100
- Khyber Medical University
-
Peshawar, KPK, Pakistan, 25100
- Trial Room Institute of Basic Medical Sciences
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 1Overweight (BMI ≥ 25kg/m2) and obese (BMI ≥ 30kg/m2) individuals.
- Both genders.
- Age 18-50 years.
Exclusion Criteria:
- Children, pregnant and lactating women
- Individuals taking medication for weight loss or undergoing any other weight loss dietary intervention.
- Individuals having lost more than 5 pounds in the past three-month period.
- Patients with any psychiatric disorders, heart, liver, kidney disease, diabetes or abnormal thyroid function.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: High Protein Low Calorie Diet
3 meals/day consumed by the participants with daily caloric intake of 800 kcal.
40-60% of the total calories added from both animal and plant proteins.
30% of the total calories added from fats.
20% of the total calories added from carbohydrates.
|
High Protein Diet: Diet consisting of 40-60% total energy from proteins, <20% total energy from carbohydrates and <30% total energy from fats.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body Composition
Time Frame: Day 0 and day 29
|
Body composition will be measured using Bioimpedance scale which will include percent body fatness, muscle mass, total body water, bone mass and body protein status.
|
Day 0 and day 29
|
|
Lipid Profile
Time Frame: Day 0 and day 29
|
Lipid profile will include concentration of total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides in blood and measured in mg/dl.
|
Day 0 and day 29
|
|
Waist Circumference
Time Frame: Day 0 and day 29
|
Waist circumference will measured in cm using a non-stretchable tape.
|
Day 0 and day 29
|
|
Hip Circumference
Time Frame: Day 0 and day 29
|
Hip circumference will measured in cm using a non-stretchable tape.
|
Day 0 and day 29
|
|
HOMA-IR
Time Frame: Day 0 and day 29
|
HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) will be reported in pmol/L.
|
Day 0 and day 29
|
|
Serum Carboxymethyl lysine levels (CML)
Time Frame: Day 0 and day 29
|
Sreum concentration of Carboxymethyl lysine (CML) will be used an advanced glycation endproduct (AGE) marker and expressed in ng/mL.
|
Day 0 and day 29
|
|
Serum Interleukinin-6 (IL-6)
Time Frame: Day 0 and day 29
|
Serum Interleukinin-6 (IL-6) will be used as marker of inflammation pg/mL.
|
Day 0 and day 29
|
|
Serum Hunger Hormone- Ghrelin
Time Frame: Day 1(Fasting and postprandial), Day 7(Fasting and postprandial) and Day 28(Fasting and postprandial).
|
Serum Hunger Hormone- Ghrelin will be used to asses satiety related sensation and expressed as pmol/l.
|
Day 1(Fasting and postprandial), Day 7(Fasting and postprandial) and Day 28(Fasting and postprandial).
|
|
Body Mass Index (BMI)
Time Frame: Day 0 and day 29
|
Body weight will be measured in Kg.
Height will be measure in cm.
Weight and height will be used to calculate body mass index (BMI) to report in Kg/m^2
|
Day 0 and day 29
|
|
Waist-to-Hip Ratio (WHR)
Time Frame: Day 0 and Day 29
|
Waist and Hip Circumference will be measured in cm.
These two measures will be used to calculate waist-to-hip ratio (WHR) as waist measurement divided by hip measurement (W⁄H).
|
Day 0 and Day 29
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, Willett WC, Manson JE. Abdominal adiposity and coronary heart disease in women. JAMA. 1998 Dec 2;280(21):1843-8. doi: 10.1001/jama.280.21.1843.
- Karra E, O'Daly OG, Choudhury AI, Yousseif A, Millership S, Neary MT, Scott WR, Chandarana K, Manning S, Hess ME, Iwakura H, Akamizu T, Millet Q, Gelegen C, Drew ME, Rahman S, Emmanuel JJ, Williams SC, Ruther UU, Bruning JC, Withers DJ, Zelaya FO, Batterham RL. A link between FTO, ghrelin, and impaired brain food-cue responsivity. J Clin Invest. 2013 Aug;123(8):3539-51. doi: 10.1172/JCI44403. Epub 2013 Jul 15.
- McMillan DC, Sattar N, McArdle CS. ABC of obesity. Obesity and cancer. BMJ. 2006 Nov 25;333(7578):1109-11. doi: 10.1136/bmj.39042.565035.BE1. No abstract available.
- Zou ZC, -J Mao L, Shi YY, Chen JH, Wang LS, Cai W. Effect of exercise combined with dietary intervention on obese children and adolescents associated with the FTO rs9939609 polymorphism. Eur Rev Med Pharmacol Sci. 2015 Dec;19(23):4569-75.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- KMU/IBMS/IRBE/2023/1209-20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.